Table III.

Treatment with anti-mouse CXCR-2-neutralizing Ab significantly reduced the intratumoral microvessel densitya

TreatmentNo. of Tumor Vessels/10 HPFs
Sq-19Neo + control Ab81 ± 11
Sq-19Neo + anti-CXCR-2 Ab57 ± 7b
Sq-19IL-17 + control Ab171 ± 31
Sq-19IL-17 + anti-CXCR-2 Ab64 ± 8c
A549Neo + control Ab75 ± 10
A549Neo + anti-CXCR-2 Ab47 ± 5d
A549IL-17 + control Ab130 ± 17
A549IL-17 + anti-CXCR-2 Ab56 ± 6e
  • a Tumor tissues were harvested from SCID mice on day 25 for Sq-19 or on day 40 for A549, immediately soaked in OCT compound, and frozen in liquid nitrogen. Sections were stained for CD31. Specimens (n = 4) were evaluated by quantifying the number of stained blood vessels in 10 selected most vascularized HPFs per tumor section. The mean number of microvessels/10 HPFs/tumor section (×200) from mice treated with anti-mouse CXCR-2-neutralizing Ab was much less than that from mice treated with control Ab. Data represent the mean number of vessels ± SD. (Sq-19Neo + control Ab versus Sq-19Neo + anti-CXCR-2 Ab,

  • b , p < 0.01; Sq-19IL-17 + control Ab vs Sq-19IL-17 + anti-CXCR-2 Ab,

  • c , p < 0.002; A549Neo + control Ab vs A549Neo + anti-CXCR-2 Ab,

  • d , p < 0.01; A549IL-17 + control Ab vs A549IL-17 + anti-CXCR-2 Ab,

  • e , p < 0.005).